Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pharmacyte Biotech Inc (PMCB)

Pharmacyte Biotech Inc (PMCB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Pharmacyte Biotech Inc 3960 HOWARD HUGHES PARKWAY SUITE 500 LAS VEGAS NV 89169 USA

www.pharmacyte.com P: 917-595-2850 F: 917-595-2851

Description:

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company. It is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). The Company's patented technology is used in the treatment of several types of cancer, including advanced, inoperable pancreatic cancer and diabetes. PharmaCyte Biotech, Inc., formerly known as Nuvilex, Inc., is based in United States.

Key Statistics

Overview:

Market Capitalization, $K 18,006
Enterprise Value, $K -50,034
Shares Outstanding, K 8,453
Annual Sales, $ 0 K
Annual Net Income, $ -4,320 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -620 K
EBIT, $ -6,260 K
EBITDA, $ -6,260 K
60-Month Beta -0.18
% of Insider Shareholders 1.03%
% of Institutional Shareholders 34.24%
Float, K 8,366
% Float 98.97%
Short Volume Ratio 0.02

Growth:

1-Year Return -28.52%
3-Year Return -91.98%
5-Year Return -96.47%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 98.46%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.65 on 03/18/24
Latest Earnings Date 03/21/24
Earnings Per Share ttm -1.58
EPS Growth vs. Prev Qtr -1.56%
EPS Growth vs. Prev Year -1,525.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-1500 on 07/12/21

PMCB Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -9.69%
Return-on-Assets % -5.86%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.58
Book Value/Share 3.64
Interest Coverage -0.28
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar